Dexfenfluramine
From Wikipedia, the free encyclopedia
 |
|
|
Dexfenfluramine
|
|
| Systematic (IUPAC) name | |
| N-Ethyl-1-[3-(trifluoromethyl)phenyl]-propan-2-amine | |
| Identifiers | |
| CAS number | |
| ATC code | A08 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C12H16F3N |
| Mol. mass | 231.257 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | 36% |
| Metabolism | ? |
| Half life | 17-20 hours |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status |
Schedule IV(US) Withdrawn from market |
| Routes | ? |
Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. It was for some years in the mid-1990s approved by the United States Food and Drug Administration for the purposes of weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was withdrawn. After it was removed in the US, dexfenfluramine was also pulled out in other global markets. It was later superseded by sibutramine, which is a safer alternative to both dexfenfluramine and fenfluramine.
The drug was manufactured by Interneuron Pharmaceuticals and marketed by Wyeth-Ayerst Laboratories. It is the enantiomer of levofenfluramine.
[edit] See also
[edit] References
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
|
||||||||
